bluebird bio Statistics
Total Valuation
bluebird bio has a market cap or net worth of GBP 35.88 million. The enterprise value is 137.79 million.
| Market Cap | 35.88M |
| Enterprise Value | 137.79M |
Important Dates
The last earnings date was Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 9.74M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +46.73% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 9.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.45 |
| PB Ratio | -0.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.89 |
| EV / Sales | 1.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.77 |
Financial Position
The company has a current ratio of 0.55
| Current Ratio | 0.55 |
| Quick Ratio | 0.26 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.94 |
| Interest Coverage | -8.97 |
Financial Efficiency
Return on equity (ROE) is -546.54% and return on invested capital (ROIC) is -37.22%.
| Return on Equity (ROE) | -546.54% |
| Return on Assets (ROA) | -28.37% |
| Return on Invested Capital (ROIC) | -37.22% |
| Return on Capital Employed (ROCE) | 1,100.96% |
| Revenue Per Employee | 324,408 |
| Profits Per Employee | -624,123 |
| Employee Count | 248 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 1.33 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -87.09% |
| 50-Day Moving Average | 7.90 |
| 200-Day Moving Average | 13.91 |
| Relative Strength Index (RSI) | 25.86 |
| Average Volume (20 Days) | 2,235 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.49 |
Income Statement
In the last 12 months, bluebird bio had revenue of GBP 80.45 million and -154.78 million in losses. Loss per share was -15.94.
| Revenue | 80.45M |
| Gross Profit | 21.82M |
| Operating Income | -162.94M |
| Pretax Income | -154.65M |
| Net Income | -154.78M |
| EBITDA | -115.48M |
| EBIT | -162.94M |
| Loss Per Share | -15.94 |
Balance Sheet
The company has 60.95 million in cash and 167.95 million in debt, giving a net cash position of -107.01 million.
| Cash & Cash Equivalents | 60.95M |
| Total Debt | 167.95M |
| Net Cash | -107.01M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -44.79M |
| Book Value Per Share | -4.57 |
| Working Capital | -108.79M |
Cash Flow
In the last 12 months, operating cash flow was -177.08 million and capital expenditures -1.30 million, giving a free cash flow of -178.38 million.
| Operating Cash Flow | -177.08M |
| Capital Expenditures | -1.30M |
| Free Cash Flow | -178.38M |
| FCF Per Share | n/a |
Margins
Gross margin is 27.12%, with operating and profit margins of -202.52% and -192.39%.
| Gross Margin | 27.12% |
| Operating Margin | -202.52% |
| Pretax Margin | -192.22% |
| Profit Margin | -192.39% |
| EBITDA Margin | -143.53% |
| EBIT Margin | -202.52% |
| FCF Margin | n/a |
Dividends & Yields
bluebird bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.73% |
| Shareholder Yield | n/a |
| Earnings Yield | -431.43% |
| FCF Yield | -497.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.05.
| Last Split Date | Dec 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
bluebird bio has an Altman Z-Score of -23.78. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.78 |
| Piotroski F-Score | n/a |